Finanzen von Smith & Nephew PLC (SNN)SNNSmith & Nephew PLC

Smith & Nephew PLC (SNN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Sports Medicine Joint Repair, accounting for 17.1% of total sales, equivalent to $483.00M. Other significant revenue streams include Knee Implants and Advanced Wound Care. Understanding this composition is critical for investors evaluating how SNN navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Smith & Nephew PLC maintains a gross margin of 70.91%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 16.31%, while the net margin is 9.78%. These profitability ratios, combined with a Return on Equity (ROE) of 11.85%, provide a clear picture of how effectively SNN converts its operational activities into shareholder value.

In the context of the broader market, SNN competes directly with industry leaders such as QGEN and BIO. With a market capitalization of $12.92B, it holds a leading position in the sector. When comparing efficiency, SNN's gross margin of 70.91% stands against QGEN's 63.28% and BIO's 53.12%. Such benchmarking helps identify whether Smith & Nephew PLC is trading at a premium or discount relative to its financial performance.

Smith & Nephew reported Q2 revenue of $1.6 billion, a 1.6% year-over-year increase, which was below expectations. However, trading profit rose by 9% to $566 million, showing effective cost control despite revenue challenges.